Okay, been doing a bit of revision. There's good, more betterer and most bestest news news. And a little negative too.
Fisrt the good, I got my latest 98k shares of Fri. at 3c. The more betterer: they went up.
The possible negative: 3c was massive resistance, should become strong support. The problem is how many of these 3c buyers are traders out to make a few $. Quite a few IMO, so I see something like 4c as another reistance unless we get some quick good news.
This is where the most bestest comes in.
REVISION
Cohort #1 was conducted on 3 patients at .3g/kg. In animal trials, optimum amounts were "greater than" 10g/kg. All 3 patients were amongst the worst, and hadn't responded to usual drugs. All three had significantly improved blood after receiving PAT-SM6. Furthermore PAT-SM6 bound to 80-100% of cancerous cells and left the non malignant ones alone. No safety issues. Can't get better than that.
Cohort #2. Dosage: 1g/kg. Again all 3 patients had failed to respond to conventional drugs. Again no safety issues and PAT-SM6 bound well. 1 patient (33%) showed stabilisation after 35 days.
Followup report ( from PLOS ONE) says PAT-SM6 binds to both cancerous cells GRP78 and LDL. Furthermore, PAT-SM6 being an all "natural" antibody, compared to the part synthetic one, has a longer half life
Cohort #3. Dosage: 3g/kg. As per the other tests all 3 patients had advanced MM. No safety issues. I patient still undergoing analysis and 1 patient out of other two (50%) showed stabilisation.
Cohort #4. Recruiting now and waiting approval. All Phase1/11a trials expected to be completed by end of year.
To date (2013) 15 out of 16 announcements have been Price Sensitive. The other being a hosting of conference. Cash has decreased from $6m to $5.23m in six months. Lower A$ has helped.
GENERAL FACTS ON MULTIPLE MYELOMA:
Currently, the main drugs used to treat MM are Revlimid, Velcade and Thalidomide. Total spend (2011) $4.4B, of which Revlimid is $3.2B. Revlimid is a derivative of Thalidomide. The total amount is expected to be over $7b by 2020. I presume these amounts are for other diseases as well. Having said that PAT-SM6 has also undergone Phase 1 testing for Melonoma as well. Currently 200,000 with MM worldwide and increasing. 5 year survival rate (30%).
STRATEGIES:
Patry's discuss either going alone or forming partnership by licensing out completely or partly. They mention 4 competitors that are also trying to develop. (I like our "natural antiboby' solution. Nevertheless I'm certainly just a layman and have difficulty getting my head around most of the chemical details.) Anyway, one the competitors have signed a deal for over $1b to research a drug called anti-CD38 also in phase 1/11a.
PAB has a MC of about $15m, CAB of $5m, thus EV of about 10m only. That seems extremely low to me compared to other bios around. Patrys also has other antibodies targetting other cancers at earlier stages and/or licensed out such as PAT-SC1.
- Forums
- ASX - By Stock
- PAB
- 2nd patient with stable disease
2nd patient with stable disease, page-34
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.4¢ |
Change
0.001(16.7%) |
Mkt cap ! $7.201M |
Open | High | Low | Value | Volume |
0.3¢ | 0.4¢ | 0.3¢ | $1.479K | 422.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
33 | 25595209 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 22489307 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
33 | 25595209 | 0.003 |
26 | 36631332 | 0.002 |
12 | 51351998 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 22489307 | 15 |
0.005 | 11004512 | 9 |
0.006 | 8546450 | 7 |
0.007 | 6426356 | 4 |
0.008 | 1221910 | 4 |
Last trade - 10.56am 08/10/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |